JP2015533163A5 - - Google Patents

Download PDF

Info

Publication number
JP2015533163A5
JP2015533163A5 JP2015536853A JP2015536853A JP2015533163A5 JP 2015533163 A5 JP2015533163 A5 JP 2015533163A5 JP 2015536853 A JP2015536853 A JP 2015536853A JP 2015536853 A JP2015536853 A JP 2015536853A JP 2015533163 A5 JP2015533163 A5 JP 2015533163A5
Authority
JP
Japan
Prior art keywords
multiple sclerosis
laquinimod
relapsing
presenting
preventing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015536853A
Other languages
English (en)
Other versions
JP2015533163A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/064061 external-priority patent/WO2014058979A2/en
Publication of JP2015533163A publication Critical patent/JP2015533163A/ja
Publication of JP2015533163A5 publication Critical patent/JP2015533163A5/ja
Pending legal-status Critical Current

Links

Claims (1)

  1. ある形態の多発性硬化症に罹患し、または臨床的に摘出された症候群を呈するヒト被験者における視床損傷を阻止または低減するための、有効量のラキニモドを含有する経口医薬組成物であって、好ましくは、前記形態の多発性硬化症は、再発−寛解型の多発性硬化症または進行性形態の多発性硬化症である経口医薬組成物。
JP2015536853A 2012-10-12 2013-10-09 多発性硬化症における視床損傷を低減するためのラキニモド Pending JP2015533163A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261713256P 2012-10-12 2012-10-12
US61/713,256 2012-10-12
PCT/US2013/064061 WO2014058979A2 (en) 2012-10-12 2013-10-09 Laquinimod for reducing thalamic damage in multiple sclerosis

Publications (2)

Publication Number Publication Date
JP2015533163A JP2015533163A (ja) 2015-11-19
JP2015533163A5 true JP2015533163A5 (ja) 2016-11-24

Family

ID=50475887

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015536853A Pending JP2015533163A (ja) 2012-10-12 2013-10-09 多発性硬化症における視床損傷を低減するためのラキニモド

Country Status (18)

Country Link
US (2) US20140107154A1 (ja)
EP (1) EP2961406A4 (ja)
JP (1) JP2015533163A (ja)
KR (1) KR20150080509A (ja)
CN (1) CN105263325A (ja)
AR (1) AR092993A1 (ja)
AU (2) AU2013329348A1 (ja)
BR (1) BR112015007782A2 (ja)
CA (1) CA2884272A1 (ja)
CL (2) CL2015000732A1 (ja)
EA (1) EA201590726A1 (ja)
HK (1) HK1218865A1 (ja)
IL (1) IL237745A0 (ja)
MX (1) MX2015004564A (ja)
PE (1) PE20151435A1 (ja)
SG (1) SG11201501874TA (ja)
TW (1) TW201420101A (ja)
WO (1) WO2014058979A2 (ja)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106063787A (zh) 2012-02-03 2016-11-02 泰华制药工业有限公司 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途
EP3225617A1 (en) 2012-02-16 2017-10-04 Teva Pharmaceutical Industries Ltd N-ethyl-n-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinoline carboxamide, preparation and uses thereof
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
JP2016510343A (ja) * 2013-02-15 2016-04-07 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドを用いる多発性硬化症の治療
TW201609098A (zh) * 2013-12-20 2016-03-16 泰瓦藥品工業有限公司 拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）於延緩亨丁頓舞蹈症進展的用途
CA2945978A1 (en) 2014-04-29 2015-11-05 Teva Pharmaceutical Industries Ltd. Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status
EA201791982A1 (ru) 2015-03-09 2020-02-17 Интекрин Терапьютикс, Инк. Способы лечения неалкогольной жировой болезни печени и/или липодистрофии
WO2017048457A1 (en) * 2015-09-18 2017-03-23 Teva Pharmaceuticals Industries Ltd. Combination of laquinimod and pridopidine to treat multiple sclerosis
US20190224186A1 (en) * 2016-09-13 2019-07-25 Intekrin Therapeutics, Inc. Treatment of multiple sclerosis with chs-131
EP3606527A1 (en) 2017-04-03 2020-02-12 Coherus Biosciences, Inc. Ppar-gamma agonist for treatment of progressive supranuclear palsy
CN113397757A (zh) * 2021-06-07 2021-09-17 温州医科大学 用于测试拉喹莫德在治疗缺血性脑卒中的作用的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2595159A1 (en) * 2005-01-13 2006-07-20 Sirtris Pharmaceuticals, Inc. Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders
JP2009543823A (ja) * 2006-07-17 2009-12-10 ノバルティス アクチエンゲゼルシャフト 免疫調節剤として使用するための胆汁酸アミドのスルホニルアミノカルボニル誘導体
AR073295A1 (es) * 2008-09-16 2010-10-28 Genentech Inc Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
ES2548999T3 (es) * 2009-06-19 2015-10-22 Teva Pharmaceutical Industries Ltd. Tratamiento de la esclerosis múltiple con laquinimod
JP5859438B2 (ja) * 2009-08-10 2016-02-10 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドを用いたｂｄｎｆ関連疾患の治療
US20130035390A1 (en) * 2010-01-13 2013-02-07 Ramot At Tel-Aviv University Ltd. Treatment of multiple sclerosis
SG10201509831XA (en) * 2010-12-07 2015-12-30 Teva Pharma Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients
WO2012131539A1 (en) * 2011-03-31 2012-10-04 Pfizer Inc. Novel bicyclic pyridinones
SG11201401330YA (en) * 2011-10-12 2014-05-29 Teva Pharma Treatment of multiple sclerosis with combination of laquinimod and fingolimod
TW201347762A (zh) * 2012-05-02 2013-12-01 Teva Pharma 高劑量拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）於治療多發性硬化症之用途

Similar Documents

Publication Publication Date Title
JP2015533163A5 (ja)
HRP20210819T1 (hr) Fenfluramin za uporabu u liječenju dravet sindroma
CL2016002132A1 (es) Uso de una cantidad de laquinimod, que sirve para preparar un medicamento para tratar un paciente humano afectado con esclerosis múltiple o que presenta un síndrome clínicamente aislado; un paquete, una cantidad de laquinimod y una composición farmacéutica del mismo.
JP2016518337A5 (ja)
JP2013520167A5 (ja)
MX355065B (es) Método y dispositivo para conmutación de cámaras.
JP2014507446A5 (ja)
JP2014515597A5 (ja)
CL2013001602A1 (es) Metodo para reducir o inhibir la progresion del nivel de fatiga en pacientes con esclerosis multiple y para proporcionarles neuroproteccion que comprende administrar oralmente laquinimod o una sal del mismo; laquinimod para reducir el nivel de fatiga, mejorar el estado funcional y entregar neuroproteccion en esclerosis multiple.
JP2015525757A5 (ja)
JP2012126725A5 (ja)
WO2015077503A8 (en) Autotaxin inhibitor compounds
BR112014010177A2 (pt) composto, composição farmacêutica, uso do composto, e, método para a profilaxia ou tratamento de um estado ou uma condição de doença
EP3682875A3 (en) Methods of treating pediatric metabolic syndrome
JP2014530840A5 (ja)
CL2014000844A1 (es) Formulacion farmaceutica oral de liberacion prolongada en forma de multiparticulas, que comprende a) 40-o-(2-hidroxi)etil-rapamicina y b) al menos un recubrimiento de liberacion prolongada.
JP2015534562A5 (ja)
AR090491A1 (es) Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fumarato de dimetilo
WO2014058979A8 (en) Laquinimod for reducing thalamic damage in multiple sclerosis
JP2015528502A5 (ja)
JP2017514871A5 (ja)
JP2012193216A5 (ja)
WO2013003669A3 (en) Compositions, methods of use, and methods of treatment
JP2014526468A5 (ja)
BR112012003280A2 (pt) composição farmacêutica para administração oral, método para tratar uma doença, uso do composto, e, composto.